INDICLOR Drug Patent Profile
✉ Email this page to a colleague
When do Indiclor patents expire, and when can generic versions of Indiclor launch?
Indiclor is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in INDICLOR is indium in-111 chloride. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 chloride profile page.
Summary for INDICLOR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Formulation / Manufacturing: | see details |
DailyMed Link: | INDICLOR at DailyMed |
US Patents and Regulatory Information for INDICLOR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | INDICLOR | indium in-111 chloride | INJECTABLE;INJECTION | 019862-001 | Dec 29, 1992 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |